DevvStream

ABCELLERA BIOLOGICS (NASDAQ: ABCL) STOCK QUOTE

Last Trade: US$4.54 0.05 1.11
Volume: 344,500
5-Day Change: -4.02%
YTD Change: -20.49%
Market Cap: US$1.330B

LATEST NEWS FROM ABCELLERA BIOLOGICS

VANCOUVER, British Columbia / Mar 19, 2024 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, April 16, 2024, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website . A replay will be... Read More
VANCOUVER, British Columbia / Mar 11, 2024 / Business Wire / AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience. “Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience,” said... Read More
VANCOUVER, British Columbia / Mar 05, 2024 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center. With its T-cell engager platform, AbCellera is expanding therapeutic opportunities for... Read More
VANCOUVER, British Columbia / Feb 23, 2024 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company’s Board of Directors for personal reasons, effective March 7, 2024. “AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field,” said Peter Thiel. “I am proud to have helped them with their mission.” Mr.... Read More
VANCOUVER, British Columbia / Feb 22, 2024 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time) KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 8:15 a.m. Pacific Time... Read More
Total revenue of $38 million, compared to $485 million in FY 2022 Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the year Net loss of $0.51 per share on a basic and diluted basis, compared to earnings of $0.56 (basic) and $0.50 (diluted) per share in 2022 VANCOUVER, British Columbia / Feb 20, 2024 / Business Wire / AbCellera (Nasdaq: ABCL) today announced financial results for... Read More
VANCOUVER, British Columbia / Jan 23, 2024 / Business Wire / AbCellera (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be... Read More
VANCOUVER, British Columbia / Dec 20, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website . A... Read More
VANCOUVER, British Columbia / Nov 16, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that management will present at the Piper Sandler 35th Annual Healthcare Conference in New York, New York on Thursday, November 30, 2023, at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera’s Investor Relations website.... Read More
New data from AbCellera’s T-cell engager platform demonstrates that diverse CD3-binding antibodies enable optimization of T-cell engager function beyond what is possible by modifying a single CD3-binder VANCOUVER, British Columbia / Nov 03, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) programs in two poster presentations at the Society for Immunotherapy of Cancer (SITC)... Read More
Total revenue of $7 million, compared to $101 million in Q3 2022 Total cumulative partnered program starts of 110, up 20% from Q3 2022 Net loss of $0.10 per share on a basic and diluted basis, compared to net earnings of $0.09 and $0.08 per share on a basic and diluted basis, respectively, in Q3 2022 VANCOUVER, British Columbia / Nov 02, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) today announced financial results for... Read More
WILMINGTON, Del. & VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer. The collaboration combines Prelude’s expertise in targeted protein degradation, medicinal... Read More
VANCOUVER, British Columbia / Oct 31, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023, at 4:30 p.m. Greenwich Mean Time (8:30 a.m. Pacific Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website . A replay... Read More
VANCOUVER, British Columbia / Oct 11, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) will announce its third quarter 2023 financial results on Thursday, November 2, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website . A replay... Read More
VANCOUVER, British Columbia / Sep 27, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1 to 5, 2023. “We have made significant progress on the application of our T-cell engager platform since we... Read More
VANCOUVER, British Columbia / Sep 20, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing multi-target collaboration with Regeneron (Nasdaq: REGN) to discover therapeutic antibodies for up to eight targets selected by Regeneron, increased from the original four. “Having successfully delivered on two challenging discovery campaigns under the original agreement, we are excited to... Read More
VANCOUVER, British Columbia / Sep 13, 2023 / Business Wire / AbCellera (Nasdaq:ABCL) announced today that it has entered into a strategic collaboration with Incyte (Nasdaq:INCY) to discover and develop therapeutic antibodies in oncology. “We are excited to partner with Incyte, which has a track record of developing first-in-class medicines and bringing them to patients in need,” said Murray McCutcheon, Ph.D., Senior Vice... Read More
Total revenue of $10 million, compared to $46 million in Q2 2022 Total cumulative partnered program starts of 106, up 20% from Q2 2022 Net loss of $0.11 per share on a basic and diluted basis, compared to a net loss of $0.02 per share on a basic and diluted basis in Q2 2022 VANCOUVER, British Columbia / Aug 03, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2023.... Read More
PTAB rejects request by Berkeley Lights to reconsider its decision denying Berkeley's argument that AbCellera’s U.S. patent is invalid VANCOUVER, British Columbia / Jul 24, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) announced that the United States Patent and Trademark Office’s (USPTO) Patent Trial and Appeal Board (PTAB) has denied a rehearing request in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc.... Read More
VANCOUVER, British Columbia / Jul 06, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) will announce its second quarter 2023 financial results on Thursday, August 3, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will... Read More
VANCOUVER, British Columbia / May 29, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, California on Tuesday, June 13, 2023, at 1:20 p.m. Pacific Time (4:20 p.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's... Read More
CA$701 million co-investment to strengthen capabilities and infrastructure for drug development, manufacturing, and clinical research in Canada AbCellera to build state-of-art facilities and technologies capable of developing new antibody medicines from a disease target to the completion of Phase 1 clinical trials AbCellera to collaborate with clinical researchers across Canada to design and conduct Phase 1 trials that... Read More
Total revenue of $12 million, compared to $317 million in Q1 2022 Total cumulative partnered program starts of 101, up 20% from Q1 2022 Net loss of $0.14 per share on a basic and diluted basis, compared to net earnings of $0.59 (basic) and $0.54 (diluted) per share in Q1 2022 VANCOUVER, British Columbia / May 04, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2023.... Read More
In-depth characterization of CD3-binding antibodies reveals molecules with binding and functional properties that are differentiated from antibodies commonly used for T-cell engager development Discovery of antibodies with high specificity for a peptide-MHC complex demonstrates capabilities for development of T-cell engagers against challenging cancer targets VANCOUVER, British Columbia / Apr 17, 2023 / Business Wire /... Read More
VANCOUVER, British Columbia / Apr 11, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, April 25, 2023, at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations... Read More
VANCOUVER, British Columbia / Apr 06, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) will announce its first quarter 2023 financial results on Thursday, May 4, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website . A replay will be... Read More
VANCOUVER, British Columbia & LONDON / Mar 22, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV). The partnership aims to provide long-lasting infectious diseases medicines to high-risk patients by... Read More
AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19. AbCellera will present the complete characterization of its panel of differentiated CD3-binding antibodies and demonstrate how it enables customized... Read More
AbCellera (Nasdaq: ABCL) today announced that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website . A replay will be available through the same link following the presentation. About AbCellera Biologics... Read More
Total revenue of $485 million, compared to $375 million in FY 2021 Total cumulative partnered program starts of 101, with 23 new starts in the year Net earnings of $0.56 per share on a basic and $0.50 on a diluted basis, compared to earnings of $0.56 (basic) and $0.48 (diluted) per share in 2021 AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2022. All financial information in this press release... Read More
AbCellera (Nasdaq: ABCL) today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website . A replay will be available through the same link following the presentation. About AbCellera... Read More
AbCellera (Nasdaq: ABCL) will announce its full year 2022 financial results on Tuesday, February 21, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference... Read More
PTAB rejects third request by Berkeley Lights for invalidation of AbCellera’s U.S. patents AbCellera (Nasdaq: ABCL) today announced that the United States Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera’s U.S. Patent No. 10,087,408 (the ‘408 Patent). AbCellera’s ‘408... Read More
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website . A replay will be available through the same link following the... Read More
AbCellera (Nasdaq: ABCL) announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. (NYSE: ABBV). The partnership will leverage AbCellera’s antibody discovery and development engine to deliver optimized development candidates for up to five targets selected by AbbVie across multiple indications. “This collaboration with AbbVie is another example of how AbCellera can extend... Read More
AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera’s antibody discovery engine with Rallybio’s clinical and commercial expertise in rare diseases to identify optimal clinical candidates and... Read More
Expanded characterization of CD3-binding antibodies includes identification of antibodies that bind regions of CD3 that are distinct from commonly used molecules Robust proof-of-concept study demonstrates T-cell engagers that potently eliminate cancer cells with minimal cytokine release AbCellera (Nasdaq: ABCL) today announced the release of new data on its T-cell engager (TCE) platform at the Society for Immunotherapy of... Read More
Total revenue of $101 million, compared to $6 million in Q3 2021 Four program starts in the quarter, bringing cumulative total to 92, up 33% from Q3 2021 Net earnings of $0.09 per share on a basic and $0.08 on a diluted basis, compared to a net loss of ($0.08) per share (basic and diluted) in Q3 2021 AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery,... Read More
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9, 2022, at 3:50 p.m. Pacific Time (6:50 p.m. Eastern Time) Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) Live audio webcasts of each presentation may be... Read More
AbCellera (Nasdaq: ABCL) announced today that Regeneron has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with AbCellera as part of a multi-target collaboration between the companies, into further preclinical development. The partnership, which commenced in March 2020 and allows for four discovery programs selected by Regeneron, leverages AbCellera’s antibody discovery... Read More
AbCellera (Nasdaq: ABCL) will announce its third quarter 2022 financial results on Tuesday, November 8, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference... Read More
AbCellera (Nasdaq: ABCL) today announced a presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022. “T-cell engagers have tremendous potential as precision oncology therapeutics by redirecting cancer-killing T cells to specific tumor targets,” said Bo Barnhart, Ph.D., VP, Translational Research at... Read More
AbCellera (Nasdaq: ABCL) today announced it has launched the second phase of its global headquarters expansion by breaking ground on its new facility in Vancouver, Canada. The 380,000-square-foot tech campus will include state-of-the-art lab and office spaces to support AbCellera’s capabilities in bringing new antibody-based medicines from target to the clinic. The expansion will accommodate the growth of AbCellera’s... Read More
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the second quarter of 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “We have further strengthened our balance sheet as we execute on our strategy, extending our competitive advantage in antibody... Read More
AbCellera (Nasdaq: ABCL) and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ proven track record in forming innovative biotechnology companies and AbCellera’s unique ability to quickly deliver lead drug candidates to bring transformational new... Read More
AbCellera (Nasdaq: ABCL) and Versant Ventures today announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs. Versant and AbCellera already have enabled three of the firm’s stealth-stage companies under previous partnerships. Under the terms of the deal, Versant portfolio companies will have rights to develop and commercialize... Read More
AbCellera (Nasdaq: ABCL) will announce its second quarter 2022 financial results on Tuesday, August 9, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference... Read More
AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab, the second antibody developed through AbCellera’s collaboration with Lilly, for approximately $275 million. The existing U.S. government supply of bebtelovimab, including the new purchase, is expected to meet present demand... Read More
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “We entered 2022 with strong momentum that we leveraged to start new drug discovery programs and demonstrate the power of our platform... Read More
AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”) announced today that they have expanded their strategic multi-target discovery collaboration, which leverages Empirico’s Precision Insights Platform TM to discover genetically validated drug targets and AbCellera’s technology to identify lead candidate antibodies against those targets. Following the rapid progress of their first collaborative program, which identified a... Read More
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022, in Toronto, Canada at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website . A replay will be available through the same link... Read More
AbCellera (Nasdaq: ABCL) will announce its first quarter 2022 financial results on Tuesday, May 10, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference... Read More
AbCellera (Nasdaq: ABCL), a technology company focused on next-generation antibody discovery, today announced the release of data on its new T cell engager platform at the American Association for Cancer Research (AACR) 2022 Annual Meeting. AbCellera’s poster presentation describes the discovery, characterization, and validation of a diverse panel of CD3-binding antibodies that can be used to develop bispecific CD3 T cell... Read More
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for full year 2021. All financial information in this press release is reported in U.S. dollars. “In 2021 we made significant advancements in executing our long-term strategy by growing our portfolio, deepening our platform to unlock new modalities, and expanding our... Read More
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will participate in a panel during the Truist Securities AI Symposium – Biotech & Tools. The panel is titled, “Integrated Platforms for AI-based Drug Discovery,” and will take place virtually on Tuesday, March 1, 2022, at 8:20 a.m. Pacific Time. A live audio webcast of the panel may be accessed through a link that will be posted on AbCellera's Investor... Read More
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 12:40 p.m. Pacific Time. A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website . A replay will be available through the same link following the... Read More
AbCellera (Nasdaq: ABCL) today announced that bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Bebtelovimab is authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg)... Read More
AbCellera (Nasdaq: ABCL) today announced Eli Lilly and Company (Lilly) has entered into a purchase agreement with the U.S. government to supply up to 600,000 doses, for at least $720 million, of investigational drug bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera’s collaboration with Lilly. The U.S. government will accept the doses of bebtelovimab if it is granted an Emergency Use Authorization... Read More
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. Dr. Lo has developed new financial engineering tools and business models for drug and device development... Read More
AbCellera (Nasdaq: ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include pediatric patients under the age of 12, including neonates (infants <1 year old). The EUA allows for bamlanivimab and etesevimab administered together in the treatment of mild to moderate COVID-19 as well as post-exposure... Read More
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today the appointment of Neil Aubuchon as Chief Commercial Officer (CCO). Mr. Aubuchon brings over 20 years of experience in strategic planning, operations, and leadership for global biopharmaceutical companies, including tenures at Amgen and Eli Lilly and Company (Lilly). As Chief Commercial... Read More
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the third quarter of 2021. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “We continue to execute on our long-term business strategy and have achieved another quarter of strong business development and growth... Read More
AbCellera (Nasdaq: ABCL) today announced an additional purchase by the U.S. government from Eli Lilly and Company (Lilly) for bamlanivimab with etesevimab for administration together. This neutralizing antibody therapy is authorized for emergency use for the treatment of mild to moderate COVID-19 or for post-exposure prophylaxis of COVID-19 in certain individuals. As part of the agreement, Lilly will supply 614,000 doses of... Read More
AbCellera (Nasdaq: ABCL) will announce its third quarter 2021 financial results on Tuesday, November 9, 2021, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. The live webcast of the earnings conference will be available through a link that will be posted on AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following... Read More
AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, “Everest”) announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest. The partnership will help to expand Everest’s portfolio of novel medicines across multiple indications, with the initial programs focusing on targets in oncology. “We are proud... Read More
AbCellera (Nasdaq: ABCL) today announced the European Commission (EC) and Eli Lilly and Company (Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with etesevimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. The agreement helps to... Read More
AbCellera (Nasdaq: ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg administered with etesevimab (LY-CoV016) 1400 mg to include post-exposure prophylaxis (PEP) to prevent SARS-CoV-2 infection or symptomatic COVID-19. The neutralizing antibodies, which were authorized together by the FDA in February 2021 to treat early... Read More
AbCellera (Nasdaq: ABCL) announced today that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage AbCellera’s AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna. “Over the past year, Moderna has demonstrated the speed and impact of its mRNA vaccine technology in... Read More
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has acquired TetraGenetics, Inc. (TetraGenetics), a biotechnology company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins, in an all-cash transaction that includes an upfront payment, the potential for payments based on the... Read More
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference on Monday, September 20, 2021, at 9:00 a.m. Pacific Time. A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera’s Investor Relations website . A replay will be available through the same link following the... Read More
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the second quarter of 2021. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “This quarter we delivered strong growth across key performance indicators related to our partnership business, including new programs... Read More
EQRx , a company committed to developing and delivering important new medicines at radically lower prices, and AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced a collaboration agreement for the discovery and development of therapeutic antibodies. The collaboration will leverage AbCellera’s AI-powered antibody discovery technology to... Read More
Tachyon Therapeutics, Inc. (Tachyon), a research and development focused biotechnology company, and AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced a collaboration to facilitate the discovery and development of a therapeutic antibody targeting LEFTY1, a member of the transforming growth factor β (TGF-β) superfamily and validated... Read More
AbCellera (Nasdaq: ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. The live webcast of the earnings conference call will be available through a link that will be posted on AbCellera’s Investor Relations website . A replay of the webcast will be available through the same link... Read More
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today that Neil Berkley has been appointed as Chief Business Officer (CBO). Mr. Berkley’s role will include leading the strategy and continued growth of AbCellera’s partnership business, which currently includes a diverse portfolio of more than 100 programs with drug developers of all sizes.... Read More
GreenStockNews
AbCellera (Nasdaq: ABCL) today announced it has secured a site in Vancouver for the construction of a Good Manufacturing Practices (GMP) manufacturing facility for the production of therapeutic antibodies, which will be the first of its kind in Canada. The 130,000-square-foot facility will expand AbCellera’s capabilities in... Read More
AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the “Selling Shareholders”), have entered into separate share purchase agreements with experienced institutional investors (the “Buyers”), pursuant to which the Buyers purchased an... Read More
In the release dated May 13, 2021, the “Program starts, cumulative” figure for the period ended March 31, 2021 in both the Key Business Metrics table and the following paragraph should read 54 instead of 52. The resulting percent change from the prior period (“Change %) in the table should read 15% instead of 11%. The corrected release reads: ABCELLERA REPORTS Q1 2021 BUSINESS RESULTS Total revenue of $203 million, up from... Read More
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2021. “Our partnership business continued to thrive in the first quarter of 2021, expanding our diversified program portfolio through collaborations with both new and existing partners,” said Carl Hansen, Ph.D., President and CEO of AbCellera.... Read More
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the Berenberg Conference USA 2021 on Tuesday, May 18, 2021 at 11:00 a.m. Pacific Time. A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera’s Investor Relations website . A replay will be available through the same link following the presentation. About AbCellera Biologics... Read More
AbCellera (Nasdaq: ABCL) and Angios GmbH (Angios) announced today that they have entered into a multi-year, multi-target collaboration to facilitate the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye. AbCellera will use its full stack, AI-powered antibody discovery platform to generate panels of antibodies for up to three Angios-selected targets to address diabetic retinopathy. “Through... Read More
GreenStockNews
AbCellera (Nasdaq: ABCL) today announced that a second antibody from its collaboration with Eli Lilly and Company (Lilly), LY-CoV1404, has entered clinical trials in patients with mild-to-moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trials to evaluate LY-CoV1404 alone and together with other monoclonal antibodies.... Read More
AbCellera (Nasdaq: ABCL), a technology company that has developed a centralized operating system for next-generation antibody discovery and development, today announced it has broken ground on an expanded global headquarters in its home city of Vancouver in anticipation of adding hundreds of employees to its current 250-person workforce over the next few years. “We’re building state-of-the-art facilities in Vancouver to... Read More
AbCellera (Nasdaq: ABCL) will announce its first-quarter 2021 financial results on Thursday, May 13, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live webcast will be available on AbCellera’s Investor Relations website at: https://investors.abcellera.com/ . Replay of the webcast will be available through the same link following the conference call. About... Read More
AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”) announced today that they have entered into a strategic multi-target discovery collaboration. Through each company’s proprietary technologies, the multi-target collaboration leverages hyper-scale datasets, machine learning, and advanced computation to both identify high-value, genetically-validated drug targets and discover novel therapeutic antibodies. Empirico will... Read More
GreenStockNews
AbCellera (Nasdaq: ABCL) and collaborators today announced the publication of research in Science Translational Medicine characterizing the high potency of bamlanivimab (LY-CoV555) to neutralize SARS-CoV-2 by uniquely binding both the up and down confirmations of the spike receptor-binding domain (RBD) and inhibiting critical... Read More
AbCellera (Nasdaq: ABCL) today announced agreements to expand its collaboration with Gilead Sciences, Inc. (Gilead) including a multi-year, multi-target antibody discovery collaboration and access to AbCellera’s humanized mouse technology, the Trianni Mouse ® . Under the financial terms of the agreements, AbCellera will receive an upfront payment and is eligible for milestone payments and royalties based on the development... Read More
AbCellera (NASDAQ: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the full year 2020 with the following highlights. “AbCellera had a breakthrough year, demonstrating strong growth across every area of the business and the effectiveness of our technology and business model through our discovery of the first monoclonal antibody... Read More
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. These results mark the second positive Phase 3 trial readout for bamlanivimab and etesevimab... Read More
AbCellera (Nasdaq: ABCL) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab. The opinion advises bamlanivimab alone and bamlanivimab administered together with etesevimab can be used for the treatment of confirmed COVID-19 in patients aged 12... Read More
AbCellera (NASDAQ: ABCL) will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time. A live audio webcast may be accessed through a link that will be posted on AbCellera’s Investor Relations website . A replay of the webcast will be available through the same link following the presentation. About AbCellera Biologics Inc. AbCellera is a technology company... Read More
AbCellera (Nasdaq: ABCL) announced today that Ester Falconer, Ph.D., has been appointed as Chief Technology Officer (CTO), effective January 28, 2021. As CTO, Dr. Falconer will lead AbCellera’s long-term strategy in the development, aggregation, and integration of technologies that improve the speed and success of therapeutic antibody discovery from target to investigational new drug application submission. “Dr. Falconer is... Read More
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), administered with a second Lilly antibody, etesevimab (LY-CoV016) 1400 mg, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at... Read More
AbCellera (Nasdaq: ABCL) will announce its fourth-quarter and full-year 2020 financial results on Monday, March 29, 2021 after the U.S. stock markets close and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. The live webcast of the earnings conference call can be accessed through a link that will be posted on AbCellera’s Investor Relations website . A replay of the webcast... Read More
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), will be evaluated together with VIR-7831, an antibody developed by Vir Biotechnology, Inc. and GlaxoSmithKline, as a potential COVID-19 therapy in low-risk patients with mild to moderate COVID-19. Bamlanivimab is currently a component in all Lilly’s antibody-based... Read More
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 2800 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 2800 mg (LY-CoV16) together significantly reduced COVID-19 related hospitalizations and deaths (collectively, “events”) in more than 1,000 high-risk patients recently diagnosed with COVID-19. Key details from the randomized, double-blind,... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS